Al-Jumaily Usama, Rjeib Hamid D Habeeb, Al-Mosawy Sabah, Faraj Safa, Metzger Monika
Department of Pediatrics, College of Medicine, University of Kerbala, Kerbala, Iraq.
Department of Pathology, College of Medicine, University of Al-Qadisiyah, Al-Qadisiyah, Iraq.
Int J Hematol Oncol Stem Cell Res. 2024 Jul 1;18(3):285-296. doi: 10.18502/ijhoscr.v18i3.16110.
Hodgkin lymphoma (HL) management varies throughout developing nations. This observational study aims to present the results of children having HL who received various combinations of chemotherapy treatment. The response-based method was used regardless of the risk classification. We recruited patients≤ 18 years of age diagnosed with HL in an Iraqi cancer center between January 2014 and December 2021. By stratifying patients, three risk categories were identified. Every patient initially received two cycles of ABVD as induction chemotherapy. Following induction chemotherapy, patients showing a full radiological response continued on ABVD chemotherapy for 4-6 cycles without receiving radiotherapy. Patients showing a modest initial response received three additional courses of COPDac next to the third cycle of ABVD, followed by radiotherapy. This study included fifty-nine patients with a median age of 7 years. Stage III patients accounted for 33.9% (n=20), then stage II (32.2%). B symptoms were present in 25 patients. Eleven children had initial splenic involvement. Fifty-two individuals (n = 19; 32.2%) had bulky disease. Mixed cellularity was the most prevalent histology (n=44). The median duration of follow-up was 2.7 years. EFS was 78% ±10%, and survival was 92% at 5-year estimation. Bulky disease was the only factor with a substantial unfavorable impact on the result. Response-based approach is a valuable strategy in nations with limited resources to prevent long-term sequelae from unnecessary radiotherapy.
霍奇金淋巴瘤(HL)在不同发展中国家的治疗方法各不相同。这项观察性研究旨在呈现接受不同化疗组合治疗的HL患儿的治疗结果。无论风险分类如何,均采用基于反应的治疗方法。我们招募了2014年1月至2021年12月期间在伊拉克一家癌症中心确诊为HL的18岁及以下患者。通过对患者进行分层,确定了三个风险类别。每位患者最初接受两个周期的ABVD作为诱导化疗。诱导化疗后,影像学完全缓解的患者继续接受ABVD化疗4 - 6个周期,不接受放疗。初始反应一般的患者在ABVD第三个周期后额外接受三个疗程的COPDac治疗,随后接受放疗。本研究纳入了59例患者,中位年龄为7岁。III期患者占33.9%(n = 20),其次是II期患者(32.2%)。25例患者出现B症状。11名儿童最初有脾脏受累。52例患者(n = 19;32.2%)有大包块病变。混合细胞型是最常见的组织学类型(n = 44)。中位随访时间为2.7年。无事件生存率为78%±10%,5年估计生存率为92%。大包块病变是对治疗结果有重大不利影响的唯一因素。在资源有限的国家,基于反应的治疗方法是一种有价值的策略,可预防不必要放疗带来的长期后遗症。